Abstract
Postprandial lipemia has emerged as an independent risk factor for coronary artery disease. In this systematic review we examined the effect of the medications used for the management of dyslipidemia on postprandial lipemia. Statins, beyond their effects on fasting lipid levels, reduce also postprandial lipemia mainly by inhibiting the production of apoB containing lipoproteins from the liver and thus increasing the clearance of triglyceride-rich lipoproteins of either liver or intestinal origin. Fibrates decrease fasting triglyceride and increase high density lipoprotein cholesterol levels. Besides, fibrates are particularly potent drugs in the reduction of postprandial lipemia; they decrease the production or triglyceride-rich lipoproteins and increase their clearance by enhancing the activity of lipoprotein lipase.
Keywords: Postprandial lipemia, statins, fibrates, chylomicron, chylomicron remnant, triglyceride-rich lipoprotein, remnantlike particle, apolipoproteins
Current Medicinal Chemistry
Title: The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Volume: 16 Issue: 2
Author(s): N. Tentolouris, I. Eleftheriadou and N. Katsilambros
Affiliation:
Keywords: Postprandial lipemia, statins, fibrates, chylomicron, chylomicron remnant, triglyceride-rich lipoprotein, remnantlike particle, apolipoproteins
Abstract: Postprandial lipemia has emerged as an independent risk factor for coronary artery disease. In this systematic review we examined the effect of the medications used for the management of dyslipidemia on postprandial lipemia. Statins, beyond their effects on fasting lipid levels, reduce also postprandial lipemia mainly by inhibiting the production of apoB containing lipoproteins from the liver and thus increasing the clearance of triglyceride-rich lipoproteins of either liver or intestinal origin. Fibrates decrease fasting triglyceride and increase high density lipoprotein cholesterol levels. Besides, fibrates are particularly potent drugs in the reduction of postprandial lipemia; they decrease the production or triglyceride-rich lipoproteins and increase their clearance by enhancing the activity of lipoprotein lipase.
Export Options
About this article
Cite this article as:
Tentolouris N., Eleftheriadou I. and Katsilambros N., The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia, Current Medicinal Chemistry 2009; 16 (2) . https://dx.doi.org/10.2174/092986709787002763
DOI https://dx.doi.org/10.2174/092986709787002763 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Agents for the Inhibition of Cholesteryl Ester Transfer Protein (CETP) and Prospects for the Future Treatment of Atherosclerosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design Context-Dependent Regulation of Nrf2/ARE Axis on Vascular Cell Function during Hyperglycemic Condition
Current Diabetes Reviews Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Investigation of Chemical Compounds, Antioxidant and Antimicrobial Properties of Teucrium arduini L. (Lamiaceae)
Current Drug Targets Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
Current Pharmaceutical Design The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Body Mass Index (BMI) and Cognitive Functions in Later Life
Current Alzheimer Research Understanding The Role of Inflammasome in Angina Pectoris
Current Protein & Peptide Science New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets